Document:

<PAGE>

                                                                   EXHIBIT 10.53

                              REVISED AND RESTATED
                       RESEARCH AND DEVELOPMENT AGREEMENT

This Revised and Restated Research and Development Agreement (the "Agreement"),
dated as of March 15, 2002 ("Execution Date"), between ARIAD Pharmaceuticals,
Inc., a Delaware corporation ("Pharmaceuticals") and ARIAD Corporation, a
Delaware corporation ("Corporation") supersedes and supplants in its entirety
the Research and License Agreement between Pharmaceuticals and Corporation dated
June 23, 1992 ("Original Agreement").

WHEREAS, Pharmaceuticals has certain patent rights and technology and has
acquired licenses to certain other patent rights and technology, for the purpose
of allowing Pharmaceuticals to develop and commercialize certain Products;

WHEREAS, Corporation has personnel experienced in the research and development
of human health care products and has, or is expected to acquire, the
facilities, equipment and employees that will permit it to carry out research
and development activities for Pharmaceuticals, with respect to such rights and
technology; and

WHEREAS, Pharmaceuticals desires to engage Corporation to perform such services
and Corporation desires to provide such services.

NOW, THEREFORE, in consideration of the foregoing premises and for other good
and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, Corporation and Pharmaceuticals hereby agree as follows:

1.     Definitions.

       Definitions. As used herein, capitalized terms shall have the respective
       meanings set forth below:

       (a)    "Pharmaceuticals Technology" shall mean all information,
              developments, discoveries, inventions, improvements, know-how,
              processes, formulas, methods, trade secrets and other intellectual
              property, whether or not patentable, whether or not copyrightable,
              now owned or hereafter developed, acquired, reduced to practice or
              conceived by Pharmaceuticals, either alone or jointly with others,
              or licensed or sublicensed to Pharmaceuticals.

       (b)    "Confidential Information" has the meaning set forth in Section
              8.1 below.

       (c)    "Improvements" shall mean all information, developments,
              discoveries, inventions, improvements (including improvements to
              Pharmaceuticals Technology), know-how, processes, formulas,
              methods, trade secrets and other intellectual property, other than
              the Pharmaceuticals Technology, whether or not patentable, whether
              or not copyrightable, which are developed, acquired, reduced to
              practice or conceived by Corporation, either alone or jointly with
              others, in carrying out Research and Development under this
              Agreement.

       (d)    "Legal Order" has the meaning set forth in Section 8.3 below.

       (e)    "Product" shall mean any article, composition, apparatus,
              substance, chemical, material, method, process or service.

       (f)    "Programs" shall mean research and development programs set forth
              by Pharmaceuticals for Research and Development to be performed by
              Corporation.
<PAGE>
       (g)    "Research and Development" shall mean research, development,
              pre-clinical and clinical testing, and related services and
              activities.

       1.1.   Singular and Plural. Singular and plural forms, as the case may
              be, of terms defined herein shall have correlative meanings.

2.     Research and Development

       2.1.   Research and Development Services. Pharmaceuticals hereby engages
              Corporation, and Corporation hereby agrees, to undertake Research
              and Development of the Pharmaceuticals Technology in accordance
              with each Program for the purpose of allowing Pharmaceuticals to
              develop, manufacture, use, sell and market one or more Products.
              During the term of this Agreement, Corporation shall use its best
              efforts to conduct the Research and Development for
              Pharmaceuticals with respect to each Program in a prudent and
              skillful manner in accordance with applicable laws, ordinances,
              rules, regulations, orders, licenses and other requirements now or
              hereafter in effect. Corporation shall obtain all labor,
              supervision, services, materials, supplies, tools, machinery and
              replacement parts thereof necessary to perform the Research and
              Development in accordance with each Program then in effect, which
              expenses shall be paid by Pharmaceuticals as described below. All
              such materials, supplies, tools, machinery and replacement parts
              thereof shall be used exclusively by Corporation to perform the
              Research and Development for Pharmaceuticals under each Program.

       2.2.   Reports and Records. Within sixty (60) days after the end of each
              calendar quarter during the term of this Agreement, Corporation
              shall provide to Pharmaceuticals a report setting forth the total
              Research and Development costs incurred during such quarter. All
              Research and Development and any other work performed under each
              Program should be duly recorded and evidenced in laboratory
              notebooks maintained by the persons working on the Program, in
              sufficient detail and in good scientific manner appropriate for
              patent and regulatory purposes. Upon the request of
              Pharmaceuticals, Corporation will provide to Pharmaceuticals a
              report setting forth (a) a summary of the work performed hereunder
              by Corporation and its employees and agents, and (b) a description
              of any material development with respect to the Programs.
              Pharmaceuticals shall also have the right, during normal business
              hours, to inspect and copy the records pertaining to the Programs
              kept by Corporation.

       2.3.   Rights to Property. As between Pharmaceuticals and Corporation,
              all right, title and interest in and to any Improvements acquired
              or developed pursuant to this Agreement, including all
              intellectual property rights therein, shall be the exclusive
              property of and are hereby assigned to Pharmaceuticals. This
              Section 2.3 shall survive the expiration or termination of this
              Agreement for any reason.

       2.4.   Exclusion from Assignment. Pharmaceuticals and Corporation
              acknowledge and agree the assignments set forth in Sections 2.3,
              5.3 and 7 shall not extend to, and do not include, any
              Improvements owned or controlled by third parties (alone or
              jointly) that Corporation does not have the right to assign; and
              to the extent any Improvements are owned or controlled by a third
              party and licensed to Corporation, Corporation hereby grants
              Pharmaceuticals a sublicense to such Improvements that is of the
              same scope and duration and includes all rights Corporation
              received under the license granted to Corporation by the third
              party, provided that Corporation has the right to sublicense its
              rights to Pharmaceuticals. This Section 2.4 shall survive the
              expiration or termination of this Agreement for any reason.

                                       2
<PAGE>
3.     Payment for Services; Timing of Payments.

       3.1.   Payments. In consideration of the Research and Development
              activities to be carried out by Corporation during the term of
              this Agreement, Pharmaceuticals shall reimburse Corporation for
              all of its Research and Development costs, and Pharmaceuticals
              shall additionally pay Corporation a fee equal to ten (10%)
              percent of all such Research and Development costs (a "Cost-Plus
              Fee").

       3.2.   Timing of Payments. If requested by Corporation, Pharmaceuticals
              shall advance funds for all Research and Development costs in
              reasonable amounts. Within sixty (60) days after the end of each
              calendar quarter, Corporation shall deliver a statement to
              Pharmaceuticals of the Research and Development costs actually
              incurred in such calendar quarter and the Cost-Plus Fee thereon,
              and Pharmaceuticals shall pay to Corporation any additional
              amounts shown to be due therefor and not yet paid.

       3.3.   Calculation of Costs. Directs costs shall be allocated on a
              reasonable and consistent basis, and charged to Pharmaceuticals
              for Research, Development and other services performed by
              Corporation for Pharmaceuticals hereunder. Corporation's
              expenditures and estimated expenditures of conducting the Research
              and Development hereunder shall be determined using Corporation's
              internal financial and accounting systems. Allocation of all
              indirect costs, including general and administrative costs, will
              be made by Corporation on a reasonable basis consistent with
              Corporation's regular internal cost accounting system.

       3.4.   Competitive Costs. All costs to be paid by Pharmaceuticals
              hereunder shall be no greater than the cost to Pharmaceuticals
              would be if Pharmaceuticals obtained similar services, materials
              or other resources from a third party similarly situated to
              Corporation.

4.     Representatives, Warranties and Covenants.

       4.1.   Representations, Warranties and Covenants of the Corporation.
              Corporation represents, warrants and covenants to Pharmaceuticals
              as follows:

              (a)    Corporation is a corporation duly organized, validly
                     existing and in good standing under the laws of the State
                     of Delaware; has all corporate power required to own its
                     property and to carry on its business as now conducted and
                     proposed to be conducted; and is qualified to do business
                     in all jurisdictions in which such qualification is
                     necessary;

              (b)    The execution, delivery and performance of this Agreement
                     have been duly authorized by all necessary corporate action
                     on the part of Corporation;

              (c)    This Agreement has been duly executed and delivered by
                     Corporation and is a legal, valid and binding obligation of
                     Corporation, enforceable against Corporation in accordance
                     with its terms;

              (d)    The execution, delivery and performance of this Agreement
                     does not and will not conflict with or contravene any
                     provisions of the certificate of incorporation or by-laws
                     of Corporation or any agreement, document, instrument,
                     indenture, lien, judgment, order or other obligation of
                     Corporation; and

              (e)    Corporation shall not knowingly misappropriate or otherwise
                     misuse, nor shall it knowingly permit of its employees,
                     consultants or agents to misappropriate or

                                       3
<PAGE>
                     otherwise misuse, any intellectual property of any third
                     party in performance of the Research and Development for a
                     Program.

       4.2.   Representation, Warranties and Covenants of Pharmaceuticals.
              Pharmaceuticals represents, warrants and covenants to Corporation
              as follows:

              (a)    Pharmaceuticals is a corporation duly organized, validly
                     existing and in good standing under the laws of the State
                     of Delaware; has all corporate power required to own its
                     property and to carry on its business as now conducted and
                     proposed to be conducted; and is qualified to do business
                     in all jurisdictions in which such qualification is
                     necessary;

              (b)    The execution, delivery and performance of this Agreement
                     have been duly authorized by all necessary corporate action
                     on the part of Pharmaceuticals;

              (c)    This Agreement has been duly executed and delivered by
                     Pharmaceuticals and is a legal, valid and binding
                     obligation of Pharmaceuticals, enforceable against
                     Pharmaceuticals in accordance with its terms; and

              (d)    The execution, delivery and performance of this Agreement
                     does not and will not conflict with or contravene any
                     provision of the certificate of incorporation or by-laws of
                     Pharmaceuticals or any agreement, document, instrument,
                     indenture, lien, judgment, order or other obligation of
                     Pharmaceuticals.

5.     Term and Termination.

       5.1.   Term. This Agreement shall be effective as of the Execution Date
              set forth on the first page of the Agreement and shall continue in
              full force and effect through December 31, 2010, unless earlier
              terminated in accordance with the terms and conditions set forth
              herein. The Agreement may be renewed upon the mutual agreement of
              the parties in their sole discretion.

       5.2.   Termination. Either party hereto may terminate this Agreement for
              any reason on sixty (60) days' written notice to the other party.

       5.3.   Prior Research and Development. Pharmaceuticals and Corporation
              acknowledge that certain research, development and other services
              were provided between the parties following the expiration of the
              Original Agreement on June 23, 1997. Therefore, the parties
              expressly agree that the terms and conditions of this Agreement
              shall apply to any such research, development or other services
              that were provided between the parties after June 23, 1992 and
              prior to the Execution Date of this Agreement (as well as to any
              Research and Development performed by the parties under this
              Agreement during its term). To the extent necessary to affect this
              intention of the parties, Corporation hereby assigns to
              Pharmaceuticals all of its right, title and interest in and to the
              Improvements existing prior to the Execution Date of this
              Agreement, and all intellectual property rights therein.
              Corporation shall cause any of its employees, consultants and
              agents to also assign any rights in the Improvements to
              Pharmaceuticals.

       5.4.   Effects of Expiration and Termination. Following expiration or
              termination of this Agreement, Corporation shall deliver to
              Pharmaceuticals all Confidential Information of Pharmaceuticals,
              including, without limitation, the laboratory notebooks and
              records of the

                                       4
<PAGE>
              Research and Development kept by Corporation, and all copies
              thereof in Corporation's possession.

       5.5.   Survival. The following provisions shall survive any expiration or
              termination of this Agreement: 1, 2.2 (during period set forth
              therein only), 2.3, 2.4, 4, 5.3, 5.4, 5.5, 6, 7, 8, 9, 10, 11, 12,
              13 and any payment obligations due as of the effective date of
              such expiration or termination.

6.     Relationship of the Parties.

       Nothing contained in this Agreement is intended, or is to be construed,
       to constitute Corporation and Pharmaceuticals partners or joint venturers
       or Corporation as an employee of Pharmaceuticals. Neither party hereto
       shall have any express or implied right or authority to assume or create
       any obligations on behalf of or in the name of the other party or to bind
       the other party to any contract, agreement o undertaking with any third
       party.

7.     Further Assurance.

       Corporation and Pharmaceuticals each agree to duly execute and deliver,
       or cause to be duly executed and delivered, such further instruments and
       do and cause to be done such further acts and things, including, without
       limitation, the execution and filing of additional assignments,
       agreements, instruments and other documents that may be necessary, or as
       the other party hereto may at any time and from time to time reasonably
       request, in connection with this Agreement or to carry out more
       effectively the provisions and purposes of, or to better assure and
       confirm unto such other party its rights under this Agreement. Without
       limiting the foregoing, Corporation expressly agrees that each of its
       employees, consultants and agents performing work under a Program has
       entered, or promptly will enter, into a written agreement assigning all
       right, title and interest to Pharmaceuticals in any Improvements
       conceived or reduced to practice by such individual pursuant to any
       Program as necessary for Pharmaceuticals to exercise its rights
       hereunder.

8.     Confidential Information.

       8.1.   Confidential Information. As used herein, "Confidential
              Information" means all information that Pharmaceuticals discloses
              to Corporation under this Agreement, all Pharmaceuticals
              Technology and all other Information deemed "Confidential
              Information" under this Agreement, provided that Confidential
              Information shall not include any information excluded under
              Section 8.2. Except to the extent expressly authorized by this
              Agreement or otherwise agreed in writing by the Parties, the
              Corporation agrees that it shall keep confidential and shall not
              publish or otherwise disclose any Confidential Information to any
              third party, and shall not use such Information for any purpose
              other than as provided for in this Agreement.

       8.2.   Exceptions. Notwithstanding Section 8.1 above, "Confidential
              Information" shall not include any information that Corporation
              can demonstrate by competent written evidence in existence at the
              time of disclosure or development (as applicable):

              (a)    Was already known to Corporation other than under an
                     obligation of confidentiality, at the time of disclosure by
                     Pharmaceuticals or, in the case of Pharmaceuticals
                     Technology, prior to its creation or discovery hereunder;

              (b)    Was generally available to the pubic or otherwise part of
                     the public domain at the time of its disclosure to
                     Corporation by Pharmaceuticals;

                                       5
<PAGE>
              (c)    Became generally available to the public or otherwise part
                     of the public domain after its disclosure and other than
                     through any act or omission of Corporation in breach of
                     this Agreement;

              (d)    Was disclosed to Corporation, other than under an
                     obligation of confidentiality to a third party, without
                     breach of any party's confidentiality obligation to
                     Pharmaceuticals; or

              (e)    Is independently developed by Corporation without using any
                     Confidential Information.

       8.3.   Permitted Disclosure. Notwithstanding the limitations in this
              Article 8, in the event that Corporation is required to disclose
              Confidential Information by any court of competent jurisdiction
              under any legal or regulatory statute, rule, order or regulation
              ("Legal Order"), Corporation shall provide Pharmaceuticals with
              immediate written notice of same so that Pharmaceuticals may have
              the opportunity to seek an appropriate protective order. If
              Pharmaceuticals does not obtain a protective order, Corporation
              shall disclose only such part of the Confidential Information as
              is specifically required by the Legal Order.

9.     Publicity.

       Neither Party shall use the name of the other Party in connection with
       any product, promotional literature, or advertising material without the
       prior written permission of the other party, which permission shall not
       be unreasonably withheld. This restriction shall not apply to materials
       used by Pharmaceuticals solely for financing or corporate partnering
       purposes or to documents available to the public that identify the
       existence of the Agreement.

10.    Successors and Assigns.

       The terms and provisions of this Agreement shall insure to the benefit
       of, and be binding upon, Corporation, Pharmaceuticals, and their
       respective successors and assigns.

11.    Governing Law.

       This Agreement shall be governed by and construed in accordance with the
       laws of the Commonwealth of Massachusetts, without regard to conflict of
       laws principles.

12.    Execution in Counterparts.

       This Agreement may be executed in any number of counterparts, each of
       which counterparts, when so executed and delivered, shall be deemed to be
       original, and all of which counterparts, taken together, shall constitute
       one and the same instrument.

                                       6
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed under seal and delivered as of the date first above written.

                                       ARIAD PHARMACEUTICALS, INC.,
                                       A DELAWARE CORPORATION

                                       By:/s/ Harvey J. Berger
                                          --------------------
                                          Harvey J. Berger
                                          Chairman and Chief Executive Officer

                                       ARIAD CORPORATION, A DELAWARE CORPORATION

                                       By:/s/ Laurie A. Allen
                                          -------------------
                                          Laurie A. Allen
                                          Senior Vice President
                                          Chief Legal Officer

                                       7<PAGE>
                                                                   EXHIBIT 10.54

                              REVISED AND RESTATED
                       RESEARCH AND DEVELOPMENT AGREEMENT

This Revised and Restated Research and Development Agreement (the "Agreement"),
dated as of March 15, 2002 ("Execution Date"), between ARIAD Gene Therapeutics,
Inc., a Delaware corporation ("AGTI") and ARIAD Corporation, a Delaware
corporation ("Corporation") supersedes and supplants in its entirety the
Research and License Agreement between AGTI and Corporation dated July 1, 1994
("Original Agreement").

WHEREAS, AGTI has certain patent rights and technology and has acquired licenses
to certain other patent rights and technology, for the purpose of allowing AGTI
to develop and commercialize certain Products;

WHEREAS, Corporation has personnel experienced in the research and development
of human health care products and has, or is expected to acquire, the
facilities, equipment and employees that will permit it to carry out research
and development activities for AGTI, with respect to such rights and technology;
and

WHEREAS, AGTI desires to engage Corporation to perform such services and
Corporation desires to provide such services.

NOW, THEREFORE, in consideration of the foregoing premises and for other good
and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, Corporation and AGTI hereby agree as follows:

1.     Definitions.

       1.1    Definitions. As used herein, capitalized terms shall have the
              respective meanings set forth below:

              (a)    "AGTI Technology" shall mean all information, developments,
                     discoveries, inventions, improvements, know-how, processes,
                     formulas, methods, trade secrets and other intellectual
                     property, whether or not patentable, whether or not
                     copyrightable, now owned or hereafter developed, acquired,
                     reduced to practice or conceived by AGTI, either alone or
                     jointly with others, or licensed or sublicensed to AGTI.

              (b)    "Confidential Information" has the meaning set forth in
                     Section 8.1 below.

              (c)    "Improvements" shall mean all information, developments,
                     discoveries, inventions, improvements (including
                     improvements to AGTI Technology), know-how, processes,
                     formulas, methods, trade secrets and other intellectual
                     property, other than the AGTI Technology, whether or not
                     patentable, whether or not copyrightable, which are
                     developed, acquired, reduced to practice or conceived by
                     Corporation, either alone or jointly with others, in
                     carrying out Research and Development under this Agreement.

              (d)    "Legal Order" has the meaning set forth in Section 8.3
                     below.

              (e)    "Product" shall mean any article, composition, apparatus,
                     substance, chemical, material, method, process or service.
<PAGE>
              (f)    "Programs" shall mean research and development programs set
                     forth by AGTI for Research and Development to be performed
                     by Corporation.

              (g)    "Research and Development" shall mean research,
                     development, clinical testing and related services and
                     activities.

       1.1.   Singular and Plural. Singular and plural forms, as the case may
              be, of terms defined herein shall have correlative meanings.

2.     Research and Development.

       2.1.   Research and Development Services. AGTI hereby engages
              Corporation, and Corporation hereby agrees, to undertake Research
              and Development of the AGTI Technology in accordance with each
              Program for the purpose of allowing AGTI to develop, manufacture,
              use, sell and market one or more Products. During the term of this
              Agreement, Corporation shall use its best efforts to conduct the
              Research and Development for AGTI with respect to each Program in
              a prudent and skillful manner in accordance with applicable laws,
              ordinances, rules, regulations, orders, licenses and other
              requirements now or hereafter in effect. Corporation shall obtain
              all labor, supervision, services, materials, supplies, tools,
              machinery and replacement parts thereof necessary to perform the
              Research and Development in accordance with each Program then in
              effect, which expenses shall be paid by AGTI as described below.
              All such materials, supplies, tools, machinery and replacement
              parts thereof shall be used exclusively by Corporation to perform
              the Research and Development for AGTI under each Program.

       2.2.   Reports and Records. Within sixty (60) days after the end of each
              calendar quarter during the term of this Agreement, Corporation
              shall provide to AGTI a report setting forth the total Research
              and Development costs incurred during such quarter. All Research
              and Development and any other work performed under each Program
              should be duly recorded and evidenced in laboratory notebooks
              maintained by the persons working on the Program, in sufficient
              detail and in good scientific manner appropriate for patent and
              regulatory purposes. Upon the request of AGTI, Corporation will
              provide to AGTI a report setting forth (a) a summary of the work
              performed hereunder by Corporation and its employees and agents,
              and (b) a description of any material development with respect to
              the Programs. AGTI shall also have the right, during normal
              business hours, to inspect and copy the records pertaining to the
              Programs kept by Corporation.

       2.3.   Rights to Property. As between AGTI and Corporation, all right,
              title and interest in and to any Improvements acquired or
              developed pursuant to this Agreement, including all intellectual
              property rights therein, shall be the exclusive property of and
              are hereby assigned to AGTI. This Section 2.3 shall survive the
              expiration or termination of this Agreement for any reason.

       2.4.   Exclusion from Assignment. AGTI and Corporation acknowledge and
              agree the assignments set forth in Sections 2.3, 5.3 and 7 shall
              not extend to, and do not include, any Improvements owned or
              controlled by third parties (alone or jointly) that Corporation
              does not have the right to assign; and to the extent any
              Improvements are owned or controlled by a third party and licensed
              to Corporation, Corporation hereby grants AGTI a sublicense to
              such Improvements that is of the same scope and duration and
              includes all rights Corporation received under the license granted
              to Corporation by the third party, provided that Corporation has
              the right to sublicense its rights to AGTI. This Section 2.4 shall
              survive the expiration or termination of this Agreement for any
              reason.

                                       2
<PAGE>
3.     Payment for Services; Timing of Payments.

       3.1.   Payments. In consideration of the Research and Development
              activities to be carried out by Corporation during the term of
              this Agreement, AGTI shall reimburse Corporation for all of its
              Research and Development costs, and AGTI shall additionally pay
              Corporation a fee equal to ten (10%) percent of all such Research
              and Development costs (a "Cost-Plus Fee").

       3.2.   Timing of Payments. If requested by Corporation, AGTI shall
              advance funds for all Research and Development costs in reasonable
              amounts. Within sixty (60) days after the end of each calendar
              quarter, Corporation shall deliver a statement to AGTI of the
              Research and Development costs actually incurred in such calendar
              quarter and the Cost-Plus Fee thereon, and AGTI shall pay to
              Corporation any additional amounts shown to be due therefor and
              not yet paid.

       3.3.   Calculation of Costs. Directs costs shall be allocated on a
              reasonable and consistent basis, and charged to AGTI for Research,
              Development and other services performed by Corporation for AGTI
              hereunder. Corporation's expenditures and estimated expenditures
              of conducting the Research and Development hereunder shall be
              determined using Corporation's internal financial and accounting
              systems. Allocation of all indirect costs, including general and
              administrative costs, will be made by Corporation on a reasonable
              basis consistent with Corporation's regular internal cost
              accounting system.

       3.4.   Competitive Costs. All costs to be paid by AGTI hereunder shall be
              no greater than the cost to AGTI would be if AGTI obtained similar
              services, materials or other resources from a third party
              similarly situated to Corporation.

4.     Representatives, Warranties and Covenants.

       4.1.   Representations, Warranties and Covenants of the Corporation.
              Corporation represents, warrants and covenants to AGTI as follows:

              (a)    Corporation is a corporation duly organized, validly
                     existing and in good standing under the laws of the State
                     of Delaware; has all corporate power required to own its
                     property and to carry on its business as now conducted and
                     proposed to be conducted; and is qualified to do business
                     in all jurisdictions in which such qualification is
                     necessary;

              (b)    The execution, delivery and performance of this Agreement
                     have been duly authorized by all necessary corporate action
                     on the part of Corporation;

              (c)    This Agreement has been duly executed and delivered by
                     Corporation and is a legal, valid and binding obligation of
                     Corporation, enforceable against Corporation in accordance
                     with its terms;

              (d)    The execution, delivery and performance of this Agreement
                     does not and will not conflict with or contravene any
                     provisions of the certificate of incorporation or by-laws
                     of Corporation or any agreement, document, instrument,
                     indenture, lien, judgment, order or other obligation of
                     Corporation; and

              (e)    Corporation shall not knowingly misappropriate or otherwise
                     misuse, nor shall it knowingly permit of its employees,
                     consultants or agents to misappropriate or

                                       3
<PAGE>
                     otherwise misuse, any intellectual property of any third
                     party in performance of the Research and Development for a
                     Program.

       4.2.   Representation, Warranties and Covenants of AGTI. AGTI represents,
              warrants and covenants to Corporation as follows:

              (a)    AGTI is a corporation duly organized, validly existing and
                     in good standing under the laws of the State of Delaware;
                     has all corporate power required to own its property and to
                     carry on its business as now conducted and proposed to be
                     conducted; and is qualified to do business in all
                     jurisdictions in which such qualification is necessary;

              (b)    The execution, delivery and performance of this Agreement
                     have been duly authorized by all necessary corporate action
                     on the part of AGTI;

              (c)    This Agreement has been duly executed and delivered by AGTI
                     and is a legal, valid and binding obligation of AGTI,
                     enforceable against AGTI in accordance with its terms; and

              (d)    The execution, delivery and performance of this Agreement
                     does not and will not conflict with or contravene any
                     provision of the certificate of incorporation or by-laws of
                     AGTI or any agreement, document, instrument, indenture,
                     lien, judgment, order or other obligation of AGTI.

5.     Term and Termination.

       5.1.   Term. This Agreement shall be effective as of the Execution Date
              set forth on the first page of the Agreement and shall continue in
              full force and effect through December 31, 2010, unless earlier
              terminated in accordance with the terms and conditions set forth
              herein. The Agreement may be renewed upon the mutual agreement of
              the parties in their sole discretion.

       5.2.   Termination. Either party hereto may terminate this Agreement for
              any reason on sixty (60) days' written notice to the other party.

       5.3.   Prior Research and Development. AGTI and Corporation acknowledge
              that certain research, development and other services were
              provided between the parties following the expiration of the
              Original Agreement on July 1, 1999. Therefore, the parties
              expressly agree that the terms and conditions of this Agreement
              shall apply to any such research, development or other services
              that were provided between the parties after July 1, 1994 and
              prior to the Execution Date of this Agreement (as well as to any
              Research and Development performed by the parties under this
              Agreement during its term). To the extent necessary to affect this
              intention of the parties, Corporation hereby assigns to AGTI all
              of its right, title and interest in and to the Improvements
              existing prior to the Execution Date of this Agreement, and all
              intellectual property rights therein. Corporation shall cause any
              of its employees, consultants and agents to also assign any rights
              in the Improvements to AGTI.

       5.4.   Effects of Expiration and Termination. Following expiration or
              termination of this Agreement, Corporation shall deliver to AGTI
              all Confidential Information of AGTI, including, without
              limitation, the laboratory notebooks and records of the Research
              and Development kept by Corporation, and all copies thereof in
              Corporation's possession.

                                       4
<PAGE>
       5.5.   Survival. The following provisions shall survive any expiration or
              termination of this Agreement: 1, 2.2 (during period set
              forth therein only), 2.3, 2.4, 4, 5.3, 5.4, 5.5, 6, 7, 8, 9, 10,
              11, 12, 13 and any payment obligations due as of the effective
              date of such expiration or termination.

6.     Relationship of the Parties.

       Nothing contained in this Agreement is intended, or is to be construed,
       to constitute Corporation and AGTI partners or joint venturers or
       Corporation as an employee of AGTI. Neither party hereto shall have any
       express or implied right or authority to assume or create any obligations
       on behalf of or in the name of the other party or to bind the other party
       to any contract, agreement or undertaking with any third party.

7.     Further Assurance.

       Corporation and AGTI each agree to duly execute and deliver, or cause to
       be duly executed and delivered, such further instruments and do and cause
       to be done such further acts and things, including, without limitation,
       the execution and filing of additional assignments, agreements,
       instruments and other documents that may be necessary, or as the other
       party hereto may at any time and from time to time reasonably request, in
       connection with this Agreement or to carry out more effectively the
       provisions and purposes of, or to better assure and confirm unto such
       other party its rights under this Agreement. Without limiting the
       foregoing, Corporation expressly agrees that each of its employees,
       consultants and agents performing work under a Program has entered, or
       promptly will enter, into a written agreement assigning all right, title
       and interest to AGTI in any Improvements conceived or reduced to practice
       by such individual pursuant to any Program as necessary for AGTI to
       exercise its rights hereunder.

8.     Confidential Information.

       8.1.   Confidential Information. As used herein, "Confidential
              Information" means all information that AGTI discloses to
              Corporation under this Agreement, all AGTI Technology and all
              other Information deemed "Confidential Information" under this
              Agreement, provided that Confidential Information shall not
              include any information excluded under Section 8.2. Except to the
              extent expressly authorized by this Agreement or otherwise agreed
              in writing by the Parties, the Corporation agrees that it shall
              keep confidential and shall not publish or otherwise disclose any
              Confidential Information to any third party, and shall not use
              such Information for any purpose other than as provided for in
              this Agreement.

       8.2.   Exceptions. Notwithstanding Section 8.1 above, "Confidential
              Information" shall not include any information that Corporation
              can demonstrate by competent written evidence in existence at the
              time of disclosure or development (as applicable):

              (a)    Was already known to Corporation other than under an
                     obligation of confidentiality, at the time of disclosure by
                     AGTI or, in the case of AGTI Technology, prior to its
                     creation or discovery hereunder;

              (b)    Was generally available to the public or otherwise part of
                     the public domain at the time of its disclosure to
                     Corporation by AGTI;

              (c)    Became generally available to the public or otherwise part
                     of the public domain after its disclosure and other than
                     through any act or omission of Corporation in breach of
                     this Agreement;

                                       5
<PAGE>
              (d)    Was disclosed to Corporation, other than under an
                     obligation of confidentiality to a third party, without
                     breach of any party's confidentiality obligation to AGTI;
                     or

              (e)    Is independently developed by Corporation without using any
                     Confidential Information.

       8.3.   Permitted Disclosure. Notwithstanding the limitations in this
              Article 8, in the event that Corporation is required to disclose
              Confidential Information by any court of competent jurisdiction
              under any legal or regulatory statute, rule, order or regulation
              ("Legal Order"), Corporation shall provide AGTI with immediate
              written notice of same so that AGTI may have the opportunity to
              seek an appropriate protective order. If AGTI does not obtain a
              protective order, Corporation shall disclose only such part of the
              Confidential Information as is specifically required by the Legal
              Order.

9.     Publicity.

       Neither Party shall use the name of the other Party in connection with
       any product, promotional literature, or advertising material without the
       prior written permission of the other party, which permission shall not
       be unreasonably withheld. This restriction shall not apply to materials
       used by AGTI solely for financing or corporate partnering purposes or to
       documents available to the public that identify the existence of the
       Agreement.

10.    Successors and Assigns.

       The terms and provisions of this Agreement shall insure to the benefit
       of, and be binding upon, Corporation, AGTI, and their respective
       successors and assigns.

11.    Governing Law.

       This Agreement shall be governed by and construed in accordance with the
       laws of the Commonwealth of Massachusetts, without regard to conflicts of
       laws principles.

12.    Execution in Counterparts.

       This Agreement may be executed in any number of counterparts, each of
       which counterparts, when so executed and delivered, shall be deemed to be
       original, and all of which counterparts, taken together, shall constitute
       one and the same instrument.

                                       6
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed under seal and delivered as of the date first above written.

                                       ARIAD GENE THERAPEUTICS, INC.,
                                       A DELAWARE CORPORTION

                                       By: /s/ Harvey J. Berger
                                       ------------------------
                                           Harvey J. Berger
                                           Chairman and Chief Executive Officer

                                       ARIAD CORPORATION, A DELAWARE CORPORTION

                                       By: /s/ Laurie A. Allen
                                       -----------------------
                                           Laurie A. Allen
                                           Senior Vice President
                                           Chief Legal Officer

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]